Clinical Trial Update: Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

Phase 2 trial update on pegaptanib sodium for exudative age-related macular degeneration, focusing on its effect on foveal thickening.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: Eyetech Pharmaceuticals | Conditions: Macular Degeneration | Phase 2 | Status: COMPLETED